A phase II study of CPX-351 in adult patients with first-relapse acute myeloid leukemia demonstrated clinical benefit in patients with poor-risk disease as defined by the European Prognostic Index.
Top-line results of the phase III MARIANNE study evaluated three HER2-targeted regimens—Kadcyla (ado-trastuzumab emtansine) plus Perjeta (pertuzumab), Kadcyla alone, and Herceptin (trastuzumab) plus taxane chemotherapy—in people with previously untreated advanced HER2-positive breast cancer.
Amgen presented data from the phase II PEAK and phase III PRIME studies evaluating first-line use of Vectibix (panitumumab) in combination with FOLFOX chemotherapy regimen in patients with wild-type RAS metastatic colorectal cancer.
Two independent phase III clinical trials, LUX-Lung 3 and LUX-Lung 6, in epidermal growth factor receptor mutation-positive metastatic non-small cell lung cancer demonstrated positive results in overall survival.
A phase III clinical trial demonstrated Jakavi (ruxolitinib) significantly improved hematocrit control without the need for phlebotomy and reduced spleen size in patients with polycythemia vera who had an inadequate response to or unacceptable side effects from hydroxyurea, as defined according to the modified European LeukemiaNet criteria.
THE UNIVERSITY OF CALIFORNIA San Diego School of Medicine and University of California, San Francisco, with support from a team of collaborators, launched the Cancer Cell Map Initiative to determine how all of the components of a cancer cell interact.
MD ANDERSON CANCER CENTER and AstraZeneca announced a multiyear strategic research collaboration to conduct multiple, parallel clinical and clinically related studies in ovarian and other gynecologic cancers, including epidemiological and outcomes studies.
TONY HUNTER, CHARLES SAWYERS, and JOSEPH SCHLESSINGER received the Frontiers of Knowledge Award in Biomedicine from the BBVA Foundation for their work in on personalized treatments of cancer.
COLUMBIA UNIVERSITY has eliminated its mesothelioma center after its director, Robert Taub, was reported to have had a long-running association with the former New York State Assembly Speaker Sheldon Silver.
JAMES ORR was appointed chair of the Florida Board of Medicine. Orr is medical director of Florida Gynecologic Oncology, a division of 21st Century Oncology. He will direct the actions of the board that oversees 68,000 Florida physicians.
